FDA Oncology Reviews Could Remain Split After CBER/CDER Reorganization
Executive Summary
FDA is understood to be considering the creation of two divisions within the Center for Drug Evaluation & Research to review oncologic products as part of the CBER/CDER reorganization
You may also be interested in...
CBER/CDER Consolidation: 20 Staff Vacancies, Two ODE VI Clinical Divisions
FDA is actively recruiting to replace 20 staffers who have left the Center for Biologics Evaluation & Research since plans to consolidate with CDER were announced a year ago
CBER/CDER Consolidation: 20 Staff Vacancies, Two ODE VI Clinical Divisions
FDA is actively recruiting to replace 20 staffers who have left the Center for Biologics Evaluation & Research since plans to consolidate with CDER were announced a year ago
CBER/CDER Consolidation: Weiss Named Acting Director Of New ODE VI
CBER Office of Therapeutics Research & Review Acting Director Sharon Risso will continue to serve as the point person for biologics staff transition questions after the consolidation with FDA's drugs center